Champions Oncolo Stock Price, News & Analysis

Champions Oncology (NASDAQ:CSBR) reported its Q1 FY2026 financial results with revenue of $14.0 million, slightly down from $14.1 million in the same period last year. The quarter was marked by the appointment of Rob Brainin as the new CEO and delivered an Adjusted EBITDA of $60,000.

The company experienced a 3% decline in service revenue but saw an increase in data license revenue. Operating expenses rose to $14.5 million, up 14.1% year-over-year, resulting in an operating loss of $527,000. Gross margin decreased to 43% from 50% in the prior year. The company maintains a strong financial position with $10.3 million in cash and no debt.

Champions Oncology (NASDAQ:CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its first quarter fiscal 2025 financial results announcement for Monday, September 15, 2025, after market close.

The company will host a conference call at 4:30 P.M. EDT to discuss the results. Investors can join via phone using access code 261008 or listen to the replay within 72 hours through the company's website or by phone using passcode 52943.

Champions Oncology (NASDAQ:CSBR) reported strong financial results for fiscal year 2025, achieving record annual revenue of $57 million, representing a 14% year-over-year increase. The company demonstrated significant profitability improvements with net income of $4.6 million and adjusted EBITDA income of $7.1 million, compared to an adjusted EBITDA loss in the previous year.

Key highlights include the successful launch of a high-margin data business generating $4.7 million in data license revenue, improved gross margins reaching 50% (up from 41%), and a strong cash position of $9.8 million with no debt. However, Q4 showed some challenges with revenue declining 12% to $12.3 million and an adjusted EBITDA loss of $1.2 million.

Champions Oncology (CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its fourth quarter and year-end financial results announcement for Wednesday, July 23, 2025, after market close.

The company will host a conference call at 4:30 P.M. EDT to discuss the results. Investors can join via phone using access code 792442 or listen to the replay within 72 hours through the company's website or by dialing with passcode 52754.

Champions Oncology (NASDAQ:CSBR), a provider of oncology-focused CRO services, has appointed Rob Brainin as its new CEO and Board member, effective August 25, 2025. Brainin, who has served on Champions' Board since 2021, will succeed Dr. Ronnie Morris, who transitions to Executive Chair after serving as CEO since 2017.

Brainin brings over 25 years of life sciences and technology experience, most recently serving as Chief Business Officer at Veracyte. The leadership change comes as Champions aims to expand beyond core CRO services into data offerings, leveraging Brainin's expertise in scaling businesses built on science and data capabilities.

Current Chairman Joel Ackerman will transition to a Director role, while Dr. Morris will remain actively involved in strategic initiatives as Executive Chair.

Champions Oncology (NASDAQ:CSBR) has announced the full commercial launch of its radiopharmaceutical services platform, marking a significant expansion in its oncology research capabilities. The company has expanded its radioactive materials license to include 10 key isotopes and completed its radiochemistry infrastructure.

The platform combines advanced radiochemistry with Champions' extensive patient-derived xenograft (PDX) tumor models, enabling comprehensive evaluation of radiolabeled agents. The company has successfully screened over 30 PDX models in collaboration with pharmaceutical and biotech partners, offering integrated workflows for in vitro, ex-vivo biodistribution, and therapeutic efficacy studies.

Champions Oncology (NASDAQ:CSBR) has secured a radioactive materials license, enabling in-house preclinical studies with various radionuclides. This development enhances the company's capabilities in developing and evaluating targeted radiotherapeutics.

The license allows Champions to combine radionuclide-based therapeutic testing with their existing patient derived xenograft (PDX) models platform under one roof. The integrated program will support drug developers in various modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.

CEO Ronnie Morris emphasized that this license represents a significant milestone in supporting biopharmaceutical partners developing next-generation radiotherapeutics, positioning the company to advance radiopharmaceutical development with enhanced translational precision.

Champions Oncology (NASDAQ:CSBR) has formed a strategic collaboration with Turbine to enhance biopharma drug discovery workflows. The partnership combines Champions' multi-omic dataset with Turbine's virtual cell simulation platform, enabling researchers to conduct rapid in silico experiments with greater precision.

The collaboration integrates Champions' clinically annotated datasets with Turbine's simulation technology to reduce dependency on traditional lab methods. This integration aims to improve various aspects of drug discovery, from target identification to generating mechanistic insights.

The partnership leverages Champions' unique offering of deeply characterized samples combined with in vivo experimental results and clinical outcome data from the same patients, which Turbine identified as critical for training and validating simulations that predict treatment responses.

Champions Oncology (Nasdaq:CSBR) reported record-breaking financial results for Q3 fiscal 2025. Total revenue increased 42% to $17.0 million, with net income reaching $4.5 million and adjusted EBITDA of $5.2 million.

The company achieved several key milestones, including signing their first data licensing deal worth up to $8.0 million and improving operational efficiency. Core services business grew 4%, while gross profit reached $10.4 million with a 61% margin. Year-to-date performance showed 23% revenue growth to $44.6 million.

Cost reduction initiatives proved successful, with total costs decreasing by 14.1% to $12.5 million compared to the previous year. The company maintains a strong financial position with $3.2 million cash on hand and no debt, while research services margin improved from 35% to 48% year-over-year.